Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | RLY-2608 |
Trade Name | |
Synonyms | RLY 2608|RLY2608 |
Drug Descriptions |
RLY-2608 selectively inhibits PIK3CA with higher selectivity and potency against mutant forms of PIK3CA (including PIK3CA E542K, PIK3CA E545K, and PIK3CA H1047R), leading to decreased downstream signaling, and potentially resulting in reduced tumor cell viability and tumor growth (Mol Cancer Ther 2021;20(12 Suppl):Abstract nr P251). |
DrugClasses | PIK3CA inhibitor 24 |
CAS Registry Number | NA |
NCIT ID | C186533 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Fulvestrant + Ribociclib + RLY-2608 | Fulvestrant RLY-2608 Ribociclib | 0 | 0 |
Fulvestrant + RLY-2608 | Fulvestrant RLY-2608 | 0 | 1 |
RLY-2608 | RLY-2608 | 10 | 1 |